Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    TG1050
Previous Study | Return to List | Next Study

Safety and Tolerability of TG1050: A Dose-finding Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02428400
Recruitment Status : Completed
First Posted : April 28, 2015
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
Transgene

Brief Summary:

Methodology:

This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection. For all cohorts, patients must be receiving antiviral treatment with either tenofovir disoproxil fumarate (TDF) or entecavir (ENT) for at least two years, and have their HBV infection well-controlled


Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Biological: TG1050 Biological: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection
Study Start Date : October 2015
Actual Primary Completion Date : November 2018
Actual Study Completion Date : November 2018

Arm Intervention/treatment
Experimental: TG1050

TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles

TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles

TG1050 Part B cohort, dose(s) and schedule to be determined

Biological: TG1050
TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer

Placebo Comparator: Placebo

Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles

Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles

Placebo Part B cohort, dose(s) and schedule to be determined

Biological: Placebo
Placebo: adenovirus reference material (ARM) buffer




Primary Outcome Measures :
  1. Safety and tolerability of TG1050 administered as single or multiple doses: Overall number of AEs, including SAEs, Grade 3 or 4 AEs, Grade 3 or 4 laboratory abnormalities, and any AE leading to a permanent discontinuation of IMP for any reason. [ Time Frame: Week 54 ]
  2. Dosage of TG1050/placebo administration for investigation in Part B of the study will be determined. [ Time Frame: Week 54 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 through 65 years of age, inclusive
  • Patients must be undetectable for neutralizing antibodies to Adenovirus serotype 5 (Ad5) (PART A ONLY)
  • Negative serum β-HCG (for women of childbearing potential only; women of non-childbearing potential are defined as a woman who has been postmenopausal for ≥ 2 years or who had had a hysterectomy, bilateral oophorectomy, or medically documented ovarian failure)
  • Female patients of childbearing potential must be willing to use double effective methods of contraception (e.g. two of the following: hormonal contraception, condom or occlusive cap, intrauterine device (IUD) or intrauterine system (IUS), male sterilisation, or true abstinence) through 3 months after the last IMP administration; male patients must agree to use a double effective method of contraception (e.g. two of the following: hormonal contraception, condom or occlusive cap, IUD or IUS, male sterilisation, or true abstinence) during heterosexual intercourse with a partner capable of becoming pregnant throughout 3 months after the last IMP administration
  • Currently on treatment for HBV monoinfection (any HBV genotypes) for at least 2 years with either the nucleos(t)ide analogue TDF or ENT
  • A history of HBV DNA < 20 IU/mL for at least 6 months before entry and HBV DNA < 20 IU/mL at screening.
  • HBsAg positive
  • HBeAg positive or HBeAg negative patients with HBV infection
  • Compensated liver disease; defined as direct or conjugated bilirubin ≤ 1.2 × ULN, PT/INR ≤ 1.2 × ULN, platelets ≥ 150,000/mm3, serum albumin ≥ 3.5 g/L, and no prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
  • ALT ≤ 1.5 x ULN. Due to its biological variability, a re-test of the ALT parameter is allowed if the ALT value at screening does not exceed 10% of the 1.5 x ULN value and all other eligibility criteria are met. In this case, the ALT re-test can be performed no more than one month after the initial ALT screening assay and has to be confirmed within 2 weeks. Values of the two ALT assays re-tests have to be below 1.5 x ULN to include the patient. In case of re-test of the ALT parameter, all hematology and biochemistry parameters will be reassessed in parallel of the second ALT re-test to ensure that they are still matching TG1050.02 eligibility criteria.• Hemoglobin ≥ 10 g/L
  • Creatinine clearance > 50mL/min
  • Neutrophils ≥ 1,500/mm3
  • Signed, written Independent Ethics Committee (IEC)-approved informed consent

Exclusion Criteria:

  • Patients with any evidence of hepatocellular carcinoma or any other liver cancer
  • Patients with α-fetoprotein > 50 ng/mL
  • Patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis Delta virus (HDV)
  • Patients with either a) medical history or evidence of cirrhosis who had any biopsy showing cirrhosis or any approved non-invasive test indicative of cirrhosis as documented in the medical source documents; OR b) either of the following at screening: transient elastography score ≥ 10.5 kPa OR a Fibrotest® Fibrosure® score of ≥ 0.48 and an aspartate aminotransferase platelet ratio Index (APRI) of ≥1. Note: If a biopsy or non-invasive test has never been performed or if a biopsy or non-invasive test has been performed but showed no cirrhosis, then b) must be followed at screening
  • Patients with a history of uncontrolled thyroid disease or abnormal thyroid stimulating hormone (TSH) levels at screening (defined as < 0.8 × lower limit of normal [LLN] or > 1.2 × ULN; patients are eligible with abnormal TSH levels if the free triiodothyronine (FT3) and free thyroxine (FT4) are within normal limits)
  • Significant concomitant medical disorder including active systemic infection or proven or suspected immunosuppressive disorder
  • History of immunodeficiency or autoimmune disease (including autoimmune hepatitis, or preexisting autoimmune or antibody-mediated disease)
  • Current or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal, renal, cardiovascular, metabolic, endocrine, neurologic, hematologic illness, major organ transplantation, or any other major medical disorder that, in the judgment of the investigator, would interfere with patient treatment, or preclude patient participation in this study; should be discussed case by case with the Sponsor
  • Pregnant or breast-feeding women
  • Prior treatment with an experimental gene therapy product or a gene therapy product
  • Prior participation in another research protocol involving an investigation medicinal product (IMP) within 4 months prior to TG1050/placebo injection
  • History of substance abuse, including alcohol abuse that in the judgment of the investigator would deem the patient as not be suitable for participation in the study
  • Patients unable or unwilling to comply with the protocol requirements

All key inclusion and exclusion criteria remain the same for patients in Part A, MD Cohort and in Part B of the study except for the following:

Patients with detectable or undetectable anti-Ad5 neutralizing antibodies are eligible (i.e. regardless of their pre-immunity to Ad5 nAb).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02428400


Locations
Layout table for location information
Canada, Alberta
Edmonton, Alberta, Canada
Canada
Calgary, Canada
Montréal, Canada
France
Grenoble, France
Lyon, France
Nancy, France
Paris, France
Strasbourg, France
Germany
Freiburg, Germany
Hamburg, Germany
Hannover, Germany
Mainz, Germany
Sponsors and Collaborators
Transgene

Layout table for additonal information
Responsible Party: Transgene
ClinicalTrials.gov Identifier: NCT02428400     History of Changes
Other Study ID Numbers: TG1050.02
First Posted: April 28, 2015    Key Record Dates
Last Update Posted: November 27, 2018
Last Verified: November 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis B, Chronic
Hepatitis
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Hepatitis, Chronic